Search

Your search keyword '"Martinez, David R."' showing total 517 results
Start Over Author "Martinez, David R."
517 results on '"Martinez, David R."'

2. Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus

Author

Dillard, Jacob A., Taft-Benz, Sharon A., Knight, Audrey C., Anderson, Elizabeth J., Pressey, Katia D., Parotti, Breantié, Martinez, Sabian A., Diaz, Jennifer L., Sarkar, Sanjay, Madden, Emily A., De la Cruz, Gabriela, Adams, Lily E., Dinnon, III, Kenneth H., Leist, Sarah R., Martinez, David R., Schäfer, Alexandra, Powers, John M., Yount, Jr., Boyd L., Castillo, Izabella N., Morales, Noah L., Burdick, Jane, Evangelista, Mia Katrina D., Ralph, Lauren M., Pankow, Nicholas C., Linnertz, Colton L., Lakshmanane, Premkumar, Montgomery, Stephanie A., Ferris, Martin T., Baric, Ralph S., Baxter, Victoria K., and Heise, Mark T.

Published
2024
Full Text
View/download PDF

3. SARS-CoV-2-related bat viruses evade human intrinsic immunity but lack efficient transmission capacity

Author

Peña-Hernández, Mario A., Alfajaro, Mia Madel, Filler, Renata B., Moriyama, Miyu, Keeler, Emma L., Ranglin, Zara E., Kong, Yong, Mao, Tianyang, Menasche, Bridget L., Mankowski, Madeleine C., Zhao, Zhe, Vogels, Chantal B. F., Hahn, Anne M., Kalinich, Chaney C., Zhang, Shuo, Huston, Nicholas, Wan, Han, Araujo-Tavares, Rafael, Lindenbach, Brett D., Homer, Robert, Pyle, Anna Marie, Martinez, David R., Grubaugh, Nathan D., Israelow, Benjamin, Iwasaki, Akiko, and Wilen, Craig B.

Published
2024
Full Text
View/download PDF

4. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease

Author

Zhou, Panpan, Song, Ge, Liu, Hejun, Yuan, Meng, He, Wan-ting, Beutler, Nathan, Zhu, Xueyong, Tse, Longping V, Martinez, David R, Schäfer, Alexandra, Anzanello, Fabio, Yong, Peter, Peng, Linghang, Dueker, Katharina, Musharrafieh, Rami, Callaghan, Sean, Capozzola, Tazio, Limbo, Oliver, Parren, Mara, Garcia, Elijah, Rawlings, Stephen A, Smith, Davey M, Nemazee, David, Jardine, Joseph G, Safonova, Yana, Briney, Bryan, Rogers, Thomas F, Wilson, Ian A, Baric, Ralph S, Gralinski, Lisa E, Burton, Dennis R, and Andrabi, Raiees

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Vaccine Related, Coronaviruses Vaccines, Rare Diseases, Coronaviruses, Infectious Diseases, Immunization, Biotechnology, Prevention, Infection, Good Health and Well Being, Humans, SARS-CoV-2, Broadly Neutralizing Antibodies, COVID-19, Antibodies, Neutralizing, Antibodies, Viral, S2 stem-helix site, SARS-CoV-2 variants of concern, broad coronavirus protection, broadly neutralizing antibodies, coronavirus spike, coronaviruses, pan-betacoronavirus vaccines
Abstract

Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly protective vaccines against novel pandemic coronaviruses and to more effectively respond to SARS-CoV-2 variants. The emergence of Omicron and subvariants of SARS-CoV-2 illustrates the limitations of solely targeting the receptor-binding domain (RBD) of the spike (S) protein. Here, we isolated a large panel of broadly neutralizing antibodies (bnAbs) from SARS-CoV-2 recovered-vaccinated donors, which targets a conserved S2 region in the betacoronavirus spike fusion machinery. Select bnAbs showed broad in vivo protection against all three deadly betacoronaviruses, SARS-CoV-1, SARS-CoV-2, and MERS-CoV, which have spilled over into humans in the past two decades. Structural studies of these bnAbs delineated the molecular basis for their broad reactivity and revealed common antibody features targetable by broad vaccination strategies. These bnAbs provide new insights and opportunities for antibody-based interventions and for developing pan-betacoronavirus vaccines.

Published
2023

5. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses

Author

He, Wan-ting, Musharrafieh, Rami, Song, Ge, Dueker, Katharina, Tse, Longping V, Martinez, David R, Schäfer, Alexandra, Callaghan, Sean, Yong, Peter, Beutler, Nathan, Torres, Jonathan L, Volk, Reid M, Zhou, Panpan, Yuan, Meng, Liu, Hejun, Anzanello, Fabio, Capozzola, Tazio, Parren, Mara, Garcia, Elijah, Rawlings, Stephen A, Smith, Davey M, Wilson, Ian A, Safonova, Yana, Ward, Andrew B, Rogers, Thomas F, Baric, Ralph S, Gralinski, Lisa E, Burton, Dennis R, and Andrabi, Raiees

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Vaccine Related, Infectious Diseases, Immunization, Emerging Infectious Diseases, Biotechnology, Prevention, Good Health and Well Being, Antibodies, Neutralizing, Antibodies, Viral, Broadly Neutralizing Antibodies, COVID-19, Humans, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Biochemistry and cell biology
Abstract

The emergence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) and potential future spillovers of SARS-like coronaviruses into humans pose a major threat to human health and the global economy. Development of broadly effective coronavirus vaccines that can mitigate these threats is needed. Here, we utilized a targeted donor selection strategy to isolate a large panel of human broadly neutralizing antibodies (bnAbs) to sarbecoviruses. Many of these bnAbs are remarkably effective in neutralizing a diversity of sarbecoviruses and against most SARS-CoV-2 VOCs, including the Omicron variant. Neutralization breadth is achieved by bnAb binding to epitopes on a relatively conserved face of the receptor-binding domain (RBD). Consistent with targeting of conserved sites, select RBD bnAbs exhibited protective efficacy against diverse SARS-like coronaviruses in a prophylaxis challenge model in vivo. These bnAbs provide new opportunities and choices for next-generation antibody prophylactic and therapeutic applications and provide a molecular basis for effective design of pan-sarbecovirus vaccines.

Published
2022

6. Host range, transmissibility and antigenicity of a pangolin coronavirus

Author

Hou, Yixuan J., Chiba, Shiho, Leist, Sarah R., Meganck, Rita M., Martinez, David R., Schäfer, Alexandra, Catanzaro, Nicholas J., Sontake, Vishwaraj, West, Ande, Edwards, Catlin E., Yount, Boyd, Lee, Rhianna E., Gallant, Samuel C., Zost, Seth J., Powers, John, Adams, Lily, Kong, Edgar F., Mattocks, Melissa, Tata, Aleksandra, Randell, Scott H., Tata, Purushothama R., Halfmann, Peter, Crowe, Jr, James E., Kawaoka, Yoshihiro, and Baric, Ralph S.

Published
2023
Full Text
View/download PDF

7. mRNA-LNP vaccine-induced CD8+ T cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies

Author

Montoya, Brian, Melo-Silva, Carolina R., Tang, Lingjuan, Kafle, Samita, Lidskiy, Peter, Bajusz, Csaba, Vadovics, Máté, Muramatsu, Hiromi, Abraham, Edit, Lipinszki, Zoltan, Chatterjee, Debotri, Scher, Gabrielle, Benitez, Juliana, Sung, Molly M.H., Tam, Ying K., Catanzaro, Nicholas J., Schäfer, Alexandra, Andino, Raul, Baric, Ralph S., Martinez, David R., Pardi, Norbert, and Sigal, Luis J.

Published
2024
Full Text
View/download PDF

8. Mapping of susceptibility loci for Ebola virus pathogenesis in mice

Author

Schäfer, Alexandra, Marzi, Andrea, Furuyama, Wakako, Catanzaro, Nicholas J., Nguyen, Cameron, Haddock, Elaine, Feldmann, Friederike, Meade-White, Kimberly, Thomas, Tina, Hubbard, Miranda L., Gully, Kendra L., Leist, Sarah R., Hock, Pablo, Bell, Timothy A., De la Cruz, Gabriela E., Midkiff, Bentley R., Martinez, David R., Shaw, Ginger D., Miller, Darla R., Vernon, Michael J., Graham, Rachel L., Cowley, Dale O., Montgomery, Stephanie A., Schughart, Klaus, de Villena, Fernando Pardo Manuel, Wilkerson, Gregory K., Ferris, Martin T., Feldmann, Heinz, and Baric, Ralph S.

Published
2024
Full Text
View/download PDF

11. Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice

Author

Martinez, David R., Schäfer, Alexandra, Gavitt, Tyler D., Mallory, Michael L., Lee, Esther, Catanzaro, Nicholas J., Chen, Haiyan, Gully, Kendra, Scobey, Trevor, Korategere, Pooja, Brown, Alecia, Smith, Lena, Parks, Robert, Barr, Maggie, Newman, Amanda, Bowman, Cindy, Powers, John M., Soderblom, Erik J., Mansouri, Katayoun, Edwards, Robert J., Baric, Ralph S., Haynes, Barton F., and Saunders, Kevin O.

Published
2023
Full Text
View/download PDF

12. Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies

Author

Young, Ellen, Carnahan, Robert H, Andrade, Daniela V, Kose, Nurgun, Nargi, Rachel S, Fritch, Ethan J, Munt, Jennifer E, Doyle, Michael P, White, Laura, Baric, Thomas J, Stoops, Mark, DeSilva, Aravinda, Tse, Longping V, Martinez, David R, Zhu, Deanna, Metz, Stefan, Wong, Marcus P, Espinosa, Diego A, Montoya, Magelda, Biering, Scott B, Sukulpolvi-Petty, Soila, Kuan, Guillermina, Balmaseda, Angel, Diamond, Michael S, Harris, Eva, Crowe, James E, and Baric, Ralph S

Subjects
Clinical Research, Immunization, Biotechnology, Biodefense, Infectious Diseases, Emerging Infectious Diseases, Prevention, Rare Diseases, Vector-Borne Diseases, Vaccine Related, Infection, Good Health and Well Being, Adolescent, Animals, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, B-Lymphocytes, Child, Child, Preschool, Chlorocebus aethiops, Dengue, Dengue Vaccines, Dengue Virus, Epitope Mapping, Epitopes, Humans, Mice, Models, Molecular, Nicaragua, Sequence Alignment, Serogroup, Vero Cells, Viral Envelope Proteins, Virion, DENV3, antigenic site, chimeric virus, dengue virus serotype 3, envelope protein, flavivirus, functional epitopes, in vivo protection, neutralizing monoclonal antibodies, Microbiology, Medical Microbiology, Immunology
Abstract

The rational design of dengue virus (DENV) vaccines requires a detailed understanding of the molecular basis for antibody-mediated immunity. The durably protective antibody response to DENV after primary infection is serotype specific. However, there is an incomplete understanding of the antigenic determinants for DENV type-specific (TS) antibodies, especially for DENV serotype 3, which has only one well-studied, strongly neutralizing human monoclonal antibody (mAb). Here, we investigated the human B cell response in children after natural DENV infection in the endemic area of Nicaragua and isolated 15 DENV3 TS mAbs recognizing the envelope (E) glycoprotein. Functional epitope mapping of these mAbs and small animal prophylaxis studies revealed a complex landscape with protective epitopes clustering in at least 6-7 antigenic sites. Potently neutralizing TS mAbs recognized sites principally in E glycoprotein domains I and II, and patterns suggest frequent recognition of quaternary structures on the surface of viral particles.

Published
2020

13. Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domains

Author

Chen, Chuan, Saville, James W., Marti, Michelle M., Schäfer, Alexandra, Cheng, Mary Hongying, Mannar, Dhiraj, Zhu, Xing, Berezuk, Alison M., Banerjee, Anupam, Sobolewski, Michele D., Kim, Andrew, Treat, Benjamin R., Da Silva Castanha, Priscila Mayrelle, Enick, Nathan, McCormick, Kevin D., Liu, Xianglei, Adams, Cynthia, Hines, Margaret Grace, Sun, Zehua, Chen, Weizao, Jacobs, Jana L., Barratt-Boyes, Simon M., Mellors, John W., Baric, Ralph S., Bahar, Ivet, Dimitrov, Dimiter S., Subramaniam, Sriram, Martinez, David R., and Li, Wei

Published
2022
Full Text
View/download PDF

14. Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine

Author

Li, Dapeng, Martinez, David R., Schäfer, Alexandra, Chen, Haiyan, Barr, Maggie, Sutherland, Laura L., Lee, Esther, Parks, Robert, Mielke, Dieter, Edwards, Whitney, Newman, Amanda, Bock, Kevin W., Minai, Mahnaz, Nagata, Bianca M., Gagne, Matthew, Douek, Daniel C., DeMarco, C. Todd, Denny, Thomas N., Oguin, III, Thomas H., Brown, Alecia, Rountree, Wes, Wang, Yunfei, Mansouri, Katayoun, Edwards, Robert J., Ferrari, Guido, Sempowski, Gregory D., Eaton, Amanda, Tang, Juanjie, Cain, Derek W., Santra, Sampa, Pardi, Norbert, Weissman, Drew, Tomai, Mark A., Fox, Christopher B., Moore, Ian N., Andersen, Hanne, Lewis, Mark G., Golding, Hana, Seder, Robert, Khurana, Surender, Baric, Ralph S., Montefiori, David C., Saunders, Kevin O., and Haynes, Barton F.

Published
2022
Full Text
View/download PDF

16. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

Author

Gebre, Makda S., Rauch, Susanne, Roth, Nicole, Yu, Jingyou, Chandrashekar, Abishek, Mercado, Noe B., He, Xuan, Liu, Jinyan, McMahan, Katherine, Martinot, Amanda, Martinez, David R., Giffin, Victoria, Hope, David, Patel, Shivani, Sellers, Daniel, Sanborn, Owen, Barrett, Julia, Liu, Xiaowen, Cole, Andrew C., Pessaint, Laurent, Valentin, Daniel, Flinchbaugh, Zack, Yalley-Ogunro, Jake, Muench, Jeanne, Brown, Renita, Cook, Anthony, Teow, Elyse, Andersen, Hanne, Lewis, Mark G., Boon, Adrianus C. M., Baric, Ralph S., Mueller, Stefan O., Petsch, Benjamin, and Barouch, Dan H.

Published
2022
Full Text
View/download PDF

17. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection

Author

Li, Wei, Chen, Chuan, Drelich, Aleksandra, Martinez, David R., Gralinski, Lisa E., Sun, Zehua, Schäfer, Alexandra, Kulkarni, Swarali S., Liu, Xianglei, Leist, Sarah R., Zhelev, Doncho V., Zhang, Liyong, Kim, Ye-Jin, Peterson, Eric C., Conard, Alex, Mellors, John W., Tseng, Chien-Te K., Falzarano, Darryl, Baric, Ralph S., and Dimitrov, Dimiter S.

Published
2020

18. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

Author

Walls, Alexandra C., Miranda, Marcos C., Schäfer, Alexandra, Pham, Minh N., Greaney, Allison, Arunachalam, Prabhu S., Navarro, Mary-Jane, Tortorici, M. Alejandra, Rogers, Kenneth, O’Connor, Megan A., Shirreff, Lisa, Ferrell, Douglas E., Bowen, John, Brunette, Natalie, Kepl, Elizabeth, Zepeda, Samantha K., Starr, Tyler, Hsieh, Ching-Lin, Fiala, Brooke, Wrenn, Samuel, Pettie, Deleah, Sydeman, Claire, Sprouse, Kaitlin R., Johnson, Max, Blackstone, Alyssa, Ravichandran, Rashmi, Ogohara, Cassandra, Carter, Lauren, Tilles, Sasha W., Rappuoli, Rino, Leist, Sarah R., Martinez, David R., Clark, Matthew, Tisch, Roland, O’Hagan, Derek T., Van Der Most, Robbert, Van Voorhis, Wesley C., Corti, Davide, McLellan, Jason S., Kleanthous, Harry, Sheahan, Timothy P., Smith, Kelly D., Fuller, Deborah H., Villinger, Francois, Bloom, Jesse, Pulendran, Bali, Baric, Ralph S., King, Neil P., and Veesler, David

Published
2021
Full Text
View/download PDF

19. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

Author

Li, Dapeng, Edwards, Robert J., Manne, Kartik, Martinez, David R., Schäfer, Alexandra, Alam, S. Munir, Wiehe, Kevin, Lu, Xiaozhi, Parks, Robert, Sutherland, Laura L., Oguin, Thomas H., III, McDanal, Charlene, Perez, Lautaro G., Mansouri, Katayoun, Gobeil, Sophie M.C., Janowska, Katarzyna, Stalls, Victoria, Kopp, Megan, Cai, Fangping, Lee, Esther, Foulger, Andrew, Hernandez, Giovanna E., Sanzone, Aja, Tilahun, Kedamawit, Jiang, Chuancang, Tse, Longping V., Bock, Kevin W., Minai, Mahnaz, Nagata, Bianca M., Cronin, Kenneth, Gee-Lai, Victoria, Deyton, Margaret, Barr, Maggie, Von Holle, Tarra, Macintyre, Andrew N., Stover, Erica, Feldman, Jared, Hauser, Blake M., Caradonna, Timothy M., Scobey, Trevor D., Rountree, Wes, Wang, Yunfei, Moody, M. Anthony, Cain, Derek W., DeMarco, C. Todd, Denny, Thomas N., Woods, Christopher W., Petzold, Elizabeth W., Schmidt, Aaron G., Teng, I-Ting, Zhou, Tongqing, Kwong, Peter D., Mascola, John R., Graham, Barney S., Moore, Ian N., Seder, Robert, Andersen, Hanne, Lewis, Mark G., Montefiori, David C., Sempowski, Gregory D., Baric, Ralph S., Acharya, Priyamvada, Haynes, Barton F., and Saunders, Kevin O.

Published
2021
Full Text
View/download PDF

24. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Author

Saunders, Kevin O., Lee, Esther, Parks, Robert, Martinez, David R., Li, Dapeng, Chen, Haiyan, Edwards, Robert J., Gobeil, Sophie, Barr, Maggie, Mansouri, Katayoun, Alam, S. Munir, Sutherland, Laura L., Cai, Fangping, Sanzone, Aja M., Berry, Madison, Manne, Kartik, and Bock, Kevin W.

Subjects
Control, Usage, Dosage and administration, Health aspects, Coronaviruses -- Health aspects -- Control, Antibodies -- Usage -- Health aspects, Viral vaccines -- Dosage and administration, Viral antibodies -- Usage -- Health aspects
Abstract

Author(s): Kevin O. Saunders [sup.1] [sup.2] [sup.3] [sup.4] , Esther Lee [sup.1] [sup.5] , Robert Parks [sup.1] [sup.5] , David R. Martinez [sup.6] , Dapeng Li [sup.1] [sup.5] , Haiyan [...], Betacoronaviruses caused the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 (SARS-CoV-2).sup.1-4. Vaccines that elicit protective immunity against SARS-CoV-2 and betacoronaviruses that circulate in animals have the potential to prevent future pandemics. Here we show that the immunization of macaques with nanoparticles conjugated with the receptor-binding domain of SARS-CoV-2, and adjuvanted with 3M-052 and alum, elicits cross-neutralizing antibody responses against bat coronaviruses, SARS-CoV and SARS-CoV-2 (including the B.1.1.7, P.1 and B.1.351 variants). Vaccination of macaques with these nanoparticles resulted in a 50% inhibitory reciprocal serum dilution (ID.sub.50) neutralization titre of 47,216 (geometric mean) for SARS-CoV-2, as well as in protection against SARS-CoV-2 in the upper and lower respiratory tracts. Nucleoside-modified mRNAs that encode a stabilized transmembrane spike or monomeric receptor-binding domain also induced cross-neutralizing antibody responses against SARS-CoV and bat coronaviruses, albeit at lower titres than achieved with the nanoparticles. These results demonstrate that current mRNA-based vaccines may provide some protection from future outbreaks of zoonotic betacoronaviruses, and provide a multimeric protein platform for the further development of vaccines against multiple (or all) betacoronaviruses. Immunization of macaques with nanoparticle-conjugated receptor-binding domain of SARS-CoV-2 adjuvanted with 3M-052 and alum results in cross-neutralizing antibodies against bat coronaviruses, SARS-CoV and SARS-CoV-2 variants, and may provide a platform for developing pan-coronavirus vaccines.

Published
2021
Full Text
View/download PDF

25. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques

Author

Yu, Jingyou, Tostanoski, Lisa H., Mercado, Noe B., McMahan, Katherine, Liu, Jinyan, Jacob-Dolan, Catherine, Chandrashekar, Abishek, Atyeo, Caroline, Martinez, David R., Anioke, Tochi, Bondzie, Esther A., Chang, Aiquan, Gardner, Sarah, Giffin, Victoria M., Hope, David L., Nampanya, Felix, Nkolola, Joseph, Patel, Shivani, Sanborn, Owen, Sellers, Daniel, Wan, Huahua, Hayes, Tammy, Bauer, Katherine, Pessaint, Laurent, Valentin, Daniel, Flinchbaugh, Zack, Brown, Renita, Cook, Anthony, Bueno-Wilkerson, Deandre, Teow, Elyse, Andersen, Hanne, Lewis, Mark G., Martinot, Amanda J., Baric, Ralph S., Alter, Galit, Wegmann, Frank, Zahn, Roland, Schuitemaker, Hanneke, and Barouch, Dan H.

Published
2021
Full Text
View/download PDF

26. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Author

Alter, Galit, Yu, Jingyou, Liu, Jinyan, Chandrashekar, Abishek, Borducchi, Erica N., Tostanoski, Lisa H., McMahan, Katherine, Jacob-Dolan, Catherine, Martinez, David R., Chang, Aiquan, Anioke, Tochi, Lifton, Michelle, Nkolola, Joseph, Stephenson, Kathryn E., Atyeo, Caroline, Shin, Sally, Fields, Paul, Kaplan, Ian, Robins, Harlan, Amanat, Fatima, Krammer, Florian, Baric, Ralph S., Le Gars, Mathieu, Sadoff, Jerald, de Groot, Anne Marit, Heerwegh, Dirk, Struyf, Frank, Douoguih, Macaya, van Hoof, Johan, Schuitemaker, Hanneke, and Barouch, Dan H.

Published
2021
Full Text
View/download PDF

27. Decoding reveals the neural representation of perceived and imagined musical sounds.

Author

Quiroga-Martinez, David R., Rubio, Gemma Fernández, Bonetti, Leonardo, Achyutuni, Kriti G., Tzovara, Athina, Knight, Robert T., and Vuust, Peter

Subjects
*BASAL ganglia, *MELODIES (Songs), *MELODY, *MAGNETOENCEPHALOGRAPHY, *HIPPOCAMPUS (Brain)
Abstract

Vividly imagining a song or a melody is a skill that many people accomplish with relatively little effort. However, we are only beginning to understand how the brain represents, holds, and manipulates these musical "thoughts." Here, we decoded perceived and imagined melodies from magnetoencephalography (MEG) brain data (N = 71) to characterize their neural representation. We found that, during perception, auditory regions represent the sensory properties of individual sounds. In contrast, a widespread network including fronto-parietal cortex, hippocampus, basal nuclei, and sensorimotor regions hold the melody as an abstract unit during both perception and imagination. Furthermore, the mental manipulation of a melody systematically changes its neural representation, reflecting volitional control of auditory images. Our work sheds light on the nature and dynamics of auditory representations, informing future research on neural decoding of auditory imagination. How does the brain process musical thoughts? This study shows that the mental manipulation of a melody systematically changes its neural representation in auditory, association, sensorimotor and subcortical areas, reflecting volitional control of auditory images. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models

Author

Li, Wei, Schäfer, Alexandra, Kulkarni, Swarali S., Liu, Xianglei, Martinez, David R., Chen, Chuan, Sun, Zehua, Leist, Sarah R., Drelich, Aleksandra, Zhang, Liyong, Ura, Marcin L., Berezuk, Alison, Chittori, Sagar, Leopold, Karoline, Mannar, Dhiraj, Srivastava, Shanti S., Zhu, Xing, Peterson, Eric C., Tseng, Chien-Te, Mellors, John W., Falzarano, Darryl, Subramaniam, Sriram, Baric, Ralph S., and Dimitrov, Dimiter S.

Published
2020
Full Text
View/download PDF

30. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

Author

Hou, Yixuan J., Okuda, Kenichi, Edwards, Caitlin E., Martinez, David R., Asakura, Takanori, Dinnon, Kenneth H., III, Kato, Takafumi, Lee, Rhianna E., Yount, Boyd L., Mascenik, Teresa M., Chen, Gang, Olivier, Kenneth N., Ghio, Andrew, Tse, Longping V., Leist, Sarah R., Gralinski, Lisa E., Schäfer, Alexandra, Dang, Hong, Gilmore, Rodney, Nakano, Satoko, Sun, Ling, Fulcher, M. Leslie, Livraghi-Butrico, Alessandra, Nicely, Nathan I., Cameron, Mark, Cameron, Cheryl, Kelvin, David J., de Silva, Aravinda, Margolis, David M., Markmann, Alena, Bartelt, Luther, Zumwalt, Ross, Martinez, Fernando J., Salvatore, Steven P., Borczuk, Alain, Tata, Purushothama R., Sontake, Vishwaraj, Kimple, Adam, Jaspers, Ilona, O’Neal, Wanda K., Randell, Scott H., Boucher, Richard C., and Baric, Ralph S.

Published
2020
Full Text
View/download PDF

31. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice

Author

Pruijssers, Andrea J., George, Amelia S., Schäfer, Alexandra, Leist, Sarah R., Gralinksi, Lisa E., Dinnon, Kenneth H., III, Yount, Boyd L., Agostini, Maria L., Stevens, Laura J., Chappell, James D., Lu, Xiaotao, Hughes, Tia M., Gully, Kendra, Martinez, David R., Brown, Ariane J., Graham, Rachel L., Perry, Jason K., Du Pont, Venice, Pitts, Jared, Ma, Bin, Babusis, Darius, Murakami, Eisuke, Feng, Joy Y., Bilello, John P., Porter, Danielle P., Cihlar, Tomas, Baric, Ralph S., Denison, Mark R., and Sheahan, Timothy P.

Published
2020
Full Text
View/download PDF

32. The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses

Author

Martinez, David R., primary, Moreira, Fernando R., additional, Catanzaro, Nicholas J., additional, Diefenbacher, Meghan V., additional, Zweigart, Mark R., additional, Gully, Kendra L., additional, De la Cruz, Gabriela, additional, Brown, Ariane J., additional, Adams, Lily E., additional, Yount, Boyd, additional, Baric, Thomas J., additional, Mallory, Michael L., additional, Conrad, Helen, additional, May, Samantha R., additional, Dong, Stephanie, additional, Scobey, D. Trevor, additional, Nguyen, Cameron, additional, Montgomery, Stephanie A., additional, Perry, Jason K., additional, Babusis, Darius, additional, Barrett, Kimberly T., additional, Nguyen, Anh-Hoa, additional, Nguyen, Anh-Quan, additional, Kalla, Rao, additional, Bannister, Roy, additional, Feng, Joy Y., additional, Cihlar, Tomas, additional, Baric, Ralph S., additional, Mackman, Richard L., additional, Bilello, John P., additional, Schäfer, Alexandra, additional, and Sheahan, Timothy P., additional

Published
2024
Full Text
View/download PDF

34. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Author

Dinnon, Kenneth H., III, Leist, Sarah R., Schäfer, Alexandra, Edwards, Caitlin E., Martinez, David R., Montgomery, Stephanie A., and West, Ande

Subjects
Control, Testing, Care and treatment, Evaluation, Models, Research, Therapeutics -- Evaluation, Therapeutics research, COVID-19 -- Control -- Care and treatment -- Research, House mouse -- Models -- Testing, Homeopathy -- Materia medica and therapeutics, Therapeutics, Experimental, Mice -- Models -- Testing
Abstract

Author(s): Kenneth H. Dinnon III [sup.1] , Sarah R. Leist [sup.2] , Alexandra Schäfer [sup.2] , Caitlin E. Edwards [sup.2] , David R. Martinez [sup.2] , Stephanie A. Montgomery [sup.3] [...], Coronaviruses are prone to transmission to new host species, as recently demonstrated by the spread to humans of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic.sup.1. Small animal models that recapitulate SARS-CoV-2 disease are needed urgently for rapid evaluation of medical countermeasures.sup.2,3. SARS-CoV-2 cannot infect wild-type laboratory mice owing to inefficient interactions between the viral spike protein and the mouse orthologue of the human receptor, angiotensin-converting enzyme 2 (ACE2).sup.4. Here we used reverse genetics.sup.5 to remodel the interaction between SARS-CoV-2 spike protein and mouse ACE2 and designed mouse-adapted SARS-CoV-2 (SARS-CoV-2 MA), a recombinant virus that can use mouse ACE2 for entry into cells. SARS-CoV-2 MA was able to replicate in the upper and lower airways of both young adult and aged BALB/c mice. SARS-CoV-2 MA caused more severe disease in aged mice, and exhibited more clinically relevant phenotypes than those seen in Hfh4-ACE2 transgenic mice, which express human ACE2 under the control of the Hfh4 (also known as Foxj1) promoter. We demonstrate the utility of this model using vaccine-challenge studies in immune-competent mice with native expression of mouse ACE2. Finally, we show that the clinical candidate interferon-[lambda]1a (IFN-[lambda]1a) potently inhibits SARS-CoV-2 replication in primary human airway epithelial cells in vitro--both prophylactic and therapeutic administration of IFN-[lambda]1a diminished SARS-CoV-2 replication in mice. In summary, the mouse-adapted SARS-CoV-2 MA model demonstrates age-related disease pathogenesis and supports the clinical use of pegylated IFN-[lambda]1a as a treatment for human COVID-19.sup.6. A model in mouse using a species-adapted virus recapitulates features of SARS-CoV-2 infection and age-related disease pathogenesis in humans, and provides a model system for rapid evaluation of medical countermeasures against coronavirus disease 2019 (COVID-19).

Published
2020
Full Text
View/download PDF

35. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Author

Zost, Seth J., Gilchuk, Pavlo, Chen, Rita E., Case, James Brett, Reidy, Joseph X., Trivette, Andrew, Nargi, Rachel S., Sutton, Rachel E., Suryadevara, Naveenchandra, Chen, Elaine C., Binshtein, Elad, Shrihari, Swathi, Chu, Helen Y., Ostrowski, Mario, Didier, Jonathan E., MacRenaris, Keith W., Jones, Taylor, Day, Samuel, Myers, Luke, Lee, F. Eun-Hyung, Nguyen, Doan C., Sanz, Ignacio, Martinez, David R., Rothlauf, Paul W., Bloyet, Louis-Marie, Whelan, Sean P.J., Baric, Ralph S., Thackray, Larissa B., Diamond, Michael S., Carnahan, Robert H., and Crowe, James E., Jr.

Subjects
Identification and classification, Care and treatment, Research, Viral proteins -- Research, Monoclonal antibodies -- Identification and classification, Immunologic research, COVID-19 -- Diagnosis -- Research -- Care and treatment, Immunological research
Abstract

Author(s): Seth J. Zost [sup.1] , Pavlo Gilchuk [sup.1] , Rita E. Chen [sup.2] [sup.3] , James Brett Case [sup.3] , Joseph X. Reidy [sup.1] , Andrew Trivette [sup.1] , [...], Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date.sup.1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms. A platform for rapid antibody discovery enabled the isolation of hundreds of human monoclonal antibodies against SARS-CoV-2 and the prioritization of potent antibody candidates for clinical trials in patients with COVID-19.

Published
2020
Full Text
View/download PDF

36. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Author

Mercado, Noe B., Zahn, Roland, Wegmann, Frank, Loos, Carolin, Chandrashekar, Abishek, Yu, Jingyou, Liu, Jinyan, Peter, Lauren, McMahan, Katherine, Tostanoski, Lisa H., He, Xuan, Martinez, David R., Rutten, Lucy, Bos, Rinke, van Manen, Danielle, Vellinga, Jort, Custers, Jerome, Langedijk, Johannes P., Kwaks, Ted, Bakkers, Mark J. G., Zuijdgeest, David, Rosendahl Huber, Sietske K., Atyeo, Caroline, Fischinger, Stephanie, Burke, John S., Feldman, Jared, Hauser, Blake M., Caradonna, Timothy M., Bondzie, Esther A., Dagotto, Gabriel, Gebre, Makda S., Hoffman, Emily, Jacob-Dolan, Catherine, Kirilova, Marinela, Li, Zhenfeng, Lin, Zijin, Mahrokhian, Shant H., Maxfield, Lori F., Nampanya, Felix, Nityanandam, Ramya, Nkolola, Joseph P., Patel, Shivani, Ventura, John D., Verrington, Kaylee, Wan, Huahua, Pessaint, Laurent, Van Ry, Alex, Blade, Kelvin, Strasbaugh, Amanda, Cabus, Mehtap, Brown, Renita, Cook, Anthony, Zouantchangadou, Serge, Teow, Elyse, Andersen, Hanne, Lewis, Mark G., Cai, Yongfei, Chen, Bing, Schmidt, Aaron G., Reeves, R. Keith, Baric, Ralph S., Lauffenburger, Douglas A., Alter, Galit, Stoffels, Paul, Mammen, Mathai, Van Hoof, Johan, Schuitemaker, Hanneke, and Barouch, Dan H.

Published
2020
Full Text
View/download PDF

37. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Author

Corbett, Kizzmekia S., Edwards, Darin K., Leist, Sarah R., Abiona, Olubukola M., Boyoglu-Barnum, Seyhan, Gillespie, Rebecca A., Himansu, Sunny, Schäfer, Alexandra, Ziwawo, Cynthia T., DiPiazza, Anthony T., Dinnon, Kenneth H., Elbashir, Sayda M., Shaw, Christine A., Woods, Angela, Fritch, Ethan J., Martinez, David R., Bock, Kevin W., Minai, Mahnaz, Nagata, Bianca M., Hutchinson, Geoffrey B., Wu, Kai, Henry, Carole, Bahl, Kapil, Garcia-Dominguez, Dario, Ma, LingZhi, Renzi, Isabella, Kong, Wing-Pui, Schmidt, Stephen D., Wang, Lingshu, Zhang, Yi, Phung, Emily, Chang, Lauren A., Loomis, Rebecca J., Altaras, Nedim Emil, Narayanan, Elisabeth, Metkar, Mihir, Presnyak, Vlad, Liu, Cuiping, Louder, Mark K., Shi, Wei, Leung, Kwanyee, Yang, Eun Sung, West, Ande, Gully, Kendra L., Stevens, Laura J., Wang, Nianshuang, Wrapp, Daniel, Doria-Rose, Nicole A., Stewart-Jones, Guillaume, Bennett, Hamilton, Alvarado, Gabriela S., Nason, Martha C., Ruckwardt, Tracy J., McLellan, Jason S., Denison, Mark R., Chappell, James D., Moore, Ian N., Morabito, Kaitlyn M., Mascola, John R., Baric, Ralph S., Carfi, Andrea, and Graham, Barney S.

Published
2020
Full Text
View/download PDF

38. Potently neutralizing and protective human antibodies against SARS-CoV-2

Author

Zost, Seth J., Gilchuk, Pavlo, Case, James Brett, Binshtein, Elad, Chen, Rita E., Nkolola, Joseph P., Schäfer, Alexandra, Reidy, Joseph X., Trivette, Andrew, Nargi, Rachel S., Sutton, Rachel E., Suryadevara, Naveenchandra, Martinez, David R., Williamson, Lauren E., Chen, Elaine C., Jones, Taylor, Day, Samuel, Myers, Luke, Hassan, Ahmed O., Kafai, Natasha M., Winkler, Emma S., Fox, Julie M., Shrihari, Swathi, Mueller, Benjamin K., Meiler, Jens, Chandrashekar, Abishek, Mercado, Noe B., Steinhardt, James J., Ren, Kuishu, Loo, Yueh-Ming, Kallewaard, Nicole L., McCune, Broc T., Keeler, Shamus P., Holtzman, Michael J., Barouch, Dan H., Gralinski, Lisa E., Baric, Ralph S., Thackray, Larissa B., Diamond, Michael S., Carnahan, Robert H., and Crowe, Jr, James E.

Published
2020
Full Text
View/download PDF

41. Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates

Author

Malewana, R. Dilshan, primary, Stalls, Victoria, additional, May, Aaron, additional, Lu, Xiaozhi, additional, Martinez, David R, additional, Schafer, Alexandra, additional, Li, Dapeng, additional, Barr, Maggie, additional, Sutherland, Laura L, additional, Lee, Esther, additional, Parks, Robert, additional, Beck, Whitney Edwards, additional, Newman, Amanda, additional, Bock, Kevin W, additional, Minai, Mahnaz, additional, Nagata, Bianca M, additional, DeMarco, C. Todd, additional, Denny, Thomas N, additional, Oguin, Thomas H, additional, Rountree, Wes, additional, Wang, Yunfei, additional, Mansouri, Katayoun, additional, Edwards, Robert J, additional, Sempowski, Gregory D, additional, Eaton, Amanda, additional, Muramatsu, Hiromi, additional, Henderson, Rory, additional, Tam, Ying, additional, Barbosa, Christopher, additional, Tang, Juanjie, additional, Cain, Derek W, additional, Santra, Sampa, additional, Moore, Ian N, additional, Andersen, Hanne, additional, Lewis, Mark G, additional, Golding, Hana, additional, Seder, Robert, additional, Khurana, Surender, additional, Montefiori, David C, additional, Pardi, Norbert, additional, Weissman, Drew, additional, Baric, Ralph S, additional, Acharya, Priyamvada, additional, Haynes, Barton F, additional, and Saunders, Kevin O, additional

Published
2023
Full Text
View/download PDF

42. A MERS-CoV antibody neutralizes a pre-emerging group 2c bat coronavirus

Author

Tse, Longping V., primary, Hou, Yixuan J., additional, McFadden, Elizabeth, additional, Lee, Rhianna E., additional, Scobey, Trevor D., additional, Leist, Sarah R., additional, Martinez, David R., additional, Meganck, Rita M., additional, Schäfer, Alexandra, additional, Yount, Boyd L., additional, Mascenik, Teresa, additional, Powers, John M., additional, Randell, Scott H., additional, Zhang, Yi, additional, Wang, Lingshu, additional, Mascola, John, additional, McLellan, Jason S., additional, and Baric, Ralph S., additional

Published
2023
Full Text
View/download PDF

43. Targeting spike glycans to inhibit SARS-CoV2 viral entry

Author

Guseman, Alex J., primary, Rennick, Linda J., additional, Nambulli, Sham, additional, Roy, Chandra N., additional, Martinez, David R., additional, Yang, Darian T., additional, Bhinderwala, Fatema, additional, Vergara, Sandra, additional, Schaefer, Alexandra, additional, Baric, Ralph S., additional, Ambrose, Zandrea, additional, Duprex, W. Paul, additional, and Gronenborn, Angela M., additional

Published
2023
Full Text
View/download PDF

46. List of Contributors

Author

Abraham, Soman N., primary, Artis, David, additional, Attia, Zayed, additional, Azegami, Tatsuhiko, additional, Babiuk, Lorne A., additional, Barry, Eileen M., additional, Beagley, Kenneth W., additional, Booth, Jayaum S., additional, Bost, Kenneth L., additional, Boyaka, Prosper N., additional, Bryan, Emily R., additional, Carlin, Nils, additional, Carr, Daniel J.J., additional, Choi, Hae Woong, additional, Chu, Hiutung, additional, Clemens, John D., additional, Coban, Cevayir, additional, Cormet-Boyaka, Estelle, additional, Crank, Michelle C., additional, Darville, Toni, additional, Derrick, Steven C., additional, Ding, Siyuan, additional, Drygiannakis, Ioannis, additional, Emmer, Kristel L., additional, Ernst, Peter B., additional, Ertl, Hildegund C.J., additional, Fujihashi, Kohtaro, additional, Fujimoto, Kosuke, additional, Gerdts, Volker, additional, Graham, Barney S., additional, Grau, Katrina R., additional, Greenberg, Harry B., additional, Hasegawa, Hideki, additional, Hashizume-Takizawa, Tomomi, additional, Hedges, Jodi F., additional, Hickey, Danica K., additional, Hirahara, Kiyoshi, additional, Holmgren, Jan, additional, Huys, Adam, additional, Ishii, Hiroshi, additional, Iwasaki, Akiko, additional, Jiang, Yanlong, additional, Jobin, Christian, additional, Johnson-Weaver, Brandi T., additional, Jutila, Mark A., additional, Karst, Stephanie M., additional, Kato, Hirotomo, additional, Kawamoto, Eiji, additional, Kawauchi, Hideyuki, additional, Kayama, Hisako, additional, Kelsall, Brian L., additional, Kemter, Andrea M., additional, Kim, Eunsoo, additional, Kiyono, Hiroshi, additional, Kobayashi, Ryoki, additional, Kollipara, Avinash, additional, Kong, Qingke, additional, Kunisawa, Jun, additional, Kurita-Ochiai, Tomoko, additional, Kweon, Mi-Na, additional, Lee, De’Ashia, additional, Lee, Michelle Sue Jann, additional, Longman, Randy S., additional, Lycke, Nils, additional, Mangold, Jesse, additional, Martinez, David R., additional, Matano, Tetsuro, additional, McDaniel, Larry S., additional, Mestecky, Jiri, additional, Metz, Maeva, additional, Meyer, Thomas F., additional, Montgomery, Micaela L., additional, Morabito, Kaitlyn M., additional, Morey, Pau, additional, Mulvey, Peter, additional, Nagler, Cathryn R., additional, Nakahashi-Ouchida, Rika, additional, Nakayama, Toshinori, additional, Ogra, Pearay L., additional, Oh, Ji Eun, additional, Park, Eun Jeong, additional, Pascual, David W., additional, Pasetti, Marcela F., additional, Permar, Sallie R., additional, Piller, Kenneth J., additional, Pope, Jillian L., additional, Pulendran, Bali, additional, Qadri, Firdausi, additional, Randall, Troy D., additional, Rhee, Joon Haeng, additional, Roland, Kenneth L., additional, Royer, Derek J., additional, Ruckwardt, Tracy J., additional, Russell, Michael W., additional, Sato, Shintaro, additional, Sen, Adrish, additional, Shimaoka, Motomu, additional, Silva-Sanchez, Aaron, additional, Staats, Herman F., additional, Suzuki, Hidehiko, additional, Svennerholm, Ann-Mari, additional, Swiatlo, Edwin, additional, Sztein, Marcelo B., additional, Takeda, Kiyoshi, additional, Toapanta, Franklin R., additional, Tomkovich, Sarah, additional, Trim, Logan, additional, Tsujimura, Yusuke, additional, Uematsu, Satoshi, additional, Venkatesan, Malabi M., additional, Wilson, Heather L., additional, Yamamoto, Hiroyuki, additional, Yamamoto, Masafumi, additional, Yasutomi, Yasuhiro, additional, and Yuki, Yoshikazu, additional

Published
2020
Full Text
View/download PDF

47. Future COVID-19 Booster Shots Will Likely Need Fresh Formulations as New Variants Emerge

Author

Martinez, David R.

Subjects
Health aspects, Influenza viruses -- Health aspects, Coronaviruses -- Health aspects, COVID-19 vaccines -- Health aspects, COVID-19 -- Health aspects, Surveillance equipment -- Health aspects
Abstract

Being up to date on COVID-19 vaccines means having https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html of the same shot at this point. Current boosters are the same formulations as the first authorized shots, https://www.nature.com/articles/d41586-021-02854-3 that [...]

Published
2022

49. Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential

Author

Martinez, David R., primary, Moreira, Fernando R., additional, Zweigart, Mark R., additional, Gully, Kendra L., additional, Cruz, Gabriela De la, additional, Brown, Ariane J., additional, Adams, Lily E., additional, Catanzaro, Nicholas, additional, Yount, Boyd, additional, Baric, Thomas J., additional, Mallory, Michael L., additional, Conrad, Helen, additional, May, Samantha R., additional, Dong, Stephanie, additional, Scobey, D. Trevor, additional, Montgomery, Stephanie A., additional, Perry, Jason, additional, Babusis, Darius, additional, Barrett, Kimberly T., additional, Nguyen, Anh-Hoa, additional, Nguyen, Anh-Quan, additional, Kalla, Rao, additional, Bannister, Roy, additional, Bilello, John P., additional, Feng, Joy Y., additional, Cihlar, Tomas, additional, Baric, Ralph S., additional, Mackman, Richard L., additional, Schäfer, Alexandra, additional, and Sheahan, Timothy P., additional

Published
2023
Full Text
View/download PDF

50. A Systems Engineering Approach to AI: Artificial intelligence systems need a holistic view to help unlock their full potential

Author

Martinez, David R.

Subjects
Algorithms, Artificial intelligence, Machine learning, Autonomous vehicles, Algorithm, Artificial intelligence, Business, Engineering and manufacturing industries
Abstract

Artificial intelligence is already turning industries on their heads, and the technology is poised to make an even greater impact on the world in the years to come. Doctors are [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results